全文获取类型
收费全文 | 6162篇 |
免费 | 318篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 138篇 |
妇产科学 | 126篇 |
基础医学 | 826篇 |
口腔科学 | 116篇 |
临床医学 | 564篇 |
内科学 | 1685篇 |
皮肤病学 | 192篇 |
神经病学 | 474篇 |
特种医学 | 114篇 |
外科学 | 619篇 |
综合类 | 19篇 |
预防医学 | 644篇 |
眼科学 | 58篇 |
药学 | 398篇 |
中国医学 | 20篇 |
肿瘤学 | 489篇 |
出版年
2023年 | 48篇 |
2022年 | 25篇 |
2021年 | 209篇 |
2020年 | 106篇 |
2019年 | 227篇 |
2018年 | 270篇 |
2017年 | 127篇 |
2016年 | 151篇 |
2015年 | 156篇 |
2014年 | 271篇 |
2013年 | 339篇 |
2012年 | 529篇 |
2011年 | 611篇 |
2010年 | 302篇 |
2009年 | 275篇 |
2008年 | 412篇 |
2007年 | 414篇 |
2006年 | 379篇 |
2005年 | 427篇 |
2004年 | 306篇 |
2003年 | 330篇 |
2002年 | 249篇 |
2001年 | 33篇 |
2000年 | 22篇 |
1999年 | 34篇 |
1998年 | 35篇 |
1997年 | 37篇 |
1996年 | 22篇 |
1995年 | 23篇 |
1994年 | 16篇 |
1993年 | 16篇 |
1992年 | 10篇 |
1991年 | 8篇 |
1990年 | 11篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 3篇 |
1984年 | 3篇 |
1983年 | 8篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1976年 | 3篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1971年 | 3篇 |
1966年 | 2篇 |
1964年 | 3篇 |
1963年 | 3篇 |
排序方式: 共有6516条查询结果,搜索用时 180 毫秒
1.
Pilar Garc a-Pe arrubia Antonio Jos Ruiz-Alcaraz Miriam Ruiz-Ballester Tamara Nadira Ram rez-P vez Mar a Mart nez-Esparza 《World journal of gastroenterology : WJG》2021,27(41):7014-7024
Macrophages are a diverse myeloid cell population involved in innate and adaptive immune responses, embryonic development, wound repair, and regulation of tissue homeostasis. These cells link the innate and adaptive immu nities and are crucial in the development and sustainment of various inflammatory diseases. Macrophages are tissue-resident cells in steady-state conditions; however, they are also recruited from blood monocytes after local pathogen invasion or tissue injury. Peritoneal macrophages vary based on their cell complexity, phenotype, and functional capabilities. These cells regulate inflammation and control bacterial infections in the ascites of decompensated cirrhotic patients. Our recent work reported several phenotypic and functional characteristics of these cells under both healthy and pathological conditions. A direct association between cell size, CD14/CD16 expression, intracellular level of GATA-6, and expression of CD206 and HLA-DR activation/maturation markers, indicate that the large peritoneal macrophage CD14highCD16high subset constitutes the mature phenotype of human resident peritoneal macrophages during homeostasis. Moreover, elevated expression of CD14/CD16 is related to the phagocytic capacity. The novel large CD14highCD16high peritoneal subpopulation is increased in the ascites of cirrhotic patients and is highly sensitive to lipopolysaccharide (LPS)-induced activation, thereby exhibiting features of inflammatory priming. Thus, phosphorylation of ERK1/2, PKB/Akt, and c-Jun is remarkably increased in response to LPS in vitro, whereas that of p38 MAPK is reduced compared with the monocyte-derived macrophages from the blood of healthy controls. Furthermore, in vitro activated monocyte-derived macrophages from ascites of cirrhotic patients secreted significantly higher levels of IL-6, IL-10, and TNF-α and lower amounts of IL-1β and IL-12 than the corresponding cells from healthy donor’s blood. Based on these results, other authors have recently reported that the surface expression level of CD206 can be used to identify mature, resident, inflammatory peritoneal macrophages in patients with cirrhosis. Soluble CD206 is released from activated large peritoneal macrophages, and increased concentrations in patients with cirrhosis and spontaneous bacterial peritonitis (SBP) indicate reduced odds of survival for 90 d. Hence, the level of soluble CD206 in ascites might be used to identify patients with SBP at risk of death. In conclusion, peritoneal macrophages present in ascites of cirrhotic patients display multiple phenotypic modifications characterized by reduced ratio of cells expressing several membrane markers, together with an increase in the ratios of complex and intermediate subpopulations and a decrease in the classic-like subset. These modifications may lead to the identification of novel pharmaceutical targets for prevention and treatment of hepatic damage. 相似文献
2.
3.
Lorena Martin-Morales Sara Manzano Maria Rodrigo-Faus Adrian Vicente-Barrueco Victor Lorca Gonzalo Núñez-Moreno Paloma Bragado Almudena Porras Trinidad Caldes Pilar Garre Alvaro Gutierrez-Uzquiza 《International journal of cancer. Journal international du cancer》2023,152(2):283-297
Matrix metalloproteinase-11 (MMP11) is an enzyme with proteolytic activity against matrix and nonmatrix proteins. Although most MMPs are secreted as inactive proenzymes and are later activated extracellularly, MMP11 is activated intracellularly by furin within the constitutive secretory pathway. It is a key factor in physiological tissue remodeling and its alteration may play an important role in the progression of epithelial malignancies and other diseases. TCGA colon and colorectal adenocarcinoma data showed that upregulation of MMP11 expression correlates with tumorigenesis and malignancy. Here, we provide evidence that a germline variant in the MMP11 gene (NM_005940: c.232C>T; p.(Pro78Ser)), identified by whole exome sequencing, can increase the tumorigenic properties of colorectal cancer (CRC) cells. P78S is located in the prodomain region, which is responsible for blocking MMP11's protease activity. This variant was detected in the proband and all the cancer-affected family members analyzed, while it was not detected in healthy relatives. In silico analyses predict that P78S could have an impact on the activation of the enzyme. Furthermore, our in vitro analyses show that the expression of P78S in HCT116 cells increases tumor cell invasion and proliferation. In summary, our results show that this variant could modify the structure of the MMP11 prodomain, producing a premature or uncontrolled activation of the enzyme that may contribute to an early CRC onset in these patients. The study of this gene in other CRC cases will provide further information about its role in CRC development, which might improve patient treatment in the future. 相似文献
4.
5.
6.
Emilie Cayssials MD Jose Torregrosa-Diaz MD Pilar Gallego-Hernanz MD Florence Tartarin MD Thomas Systchenko MD Natacha Maillard MD Déborah Desmier MD Antoine Machet MD Emmanuel Fleck MD Anne Corby MD Carine Motard MD Guillaume Denis MD André Herbelin PhD Jean-Marc Gombert MD PhD Lydia Roy MD Stéphanie Ragot PharmD PhD Xavier Leleu MD PhD François Guilhot MD Jean-Claude Chomel PharmD PhD 《Cancer》2020,126(15):3438-3447
7.
Alejandro I. Lorenzo-Pouso Mario Pérez-Sayáns Cintia Chamorro-Petronacci Pilar Gándara-Vila Pía López-Jornet Javier Carballo Abel García-García 《Journal of oral pathology & medicine》2020,49(3):190-200
Consensus has yet to be reached about the prevention and treatment of medication-related osteonecrosis of the jaw (MRONJ), which is a treatment sequela of several antiresorptive therapies and other pharmaceutical interventions. Several epidemiologic studies have identified periodontal disease (PD) as a risk factor for this outcome. Thus, the objective of this systematic review and meta-analysis was to investigate this association and its magnitude. A systematic search in MEDLINE via PubMed, Scopus and ISI Web of Science, and a meta-analysis were undertaken. Observational studies that gathered information regarding prefixed definitions for both outcomes were selected, and the relevant information was then extracted, and their risk of bias was evaluated using the Newcastle-Ottawa Scale. The protocol of the study was registered on PROSPERO (CRD42019125646). The initial search yielded 757 eligible records, of which 12 were deemed adequate for inclusion (5 cohort studies and 7 case-control studies). On a random-effects meta-analysis, the risk of PD in MRONJ-affected sites compared with at-risk non-affected patients was significantly greater, with a risk ratio of 2.75 (95% CI: 1.67-4.52). Nonetheless, from a pooled analysis of three standardized periodontal measures (ie plaque index, clinical attachment loss and probing depth) no significant results were obtained. MRONJ appears to be associated with an increase in prevalence of PD. The direction of this association, and the factors influencing it must be investigated using further prospective data, and likewise, the possibility for using periodontal therapy as a prevention strategy must be looked into. Periodontal screening needs to be made an indispensable requisite for clinicians in order to establish a correct multidisciplinary approach in MRONJ. 相似文献
8.
Renée T. Fortner Anika Hüsing Laure Dossus Anne Tjønneland Kim Overvad Christina C. Dahm Patrick Arveux Agnès Fournier Marina Kvaskoff Matthias B. Schulze Manuela Bergmann Antonia Trichopoulou Anna Karakatsani Carlo La Vecchia Giovanna Masala Valeria Pala Amalia Mattiello Rosario Tumino Fulvio Ricceri Carla H. van Gils Evelyn M. Monninkhof Catalina Bonet José Ramón Quirós Maria-Jose Sanchez Daniel-Ángel Rodríguez-Palacios Aurelio B Gurrea Pilar Amiano Naomi E. Allen Ruth C. Travis Marc J. Gunter Vivian Viallon Elisabete Weiderpass Elio Riboli Rudolf Kaaks 《International journal of cancer. Journal international du cancer》2020,147(5):1325-1333
Endometrial cancer (EC) incidence rates vary ~10-fold worldwide, in part due to variation in EC risk factor profiles. Using an EC risk model previously developed in the European EPIC cohort, we evaluated the prevention potential of modified EC risk factor patterns and whether differences in EC incidence between a European population and low-risk countries can be explained by differences in these patterns. Predicted EC incidence rates were estimated over 10 years of follow-up for the cohort before and after modifying risk factor profiles. Risk factors considered were: body mass index (BMI, kg/m2), use of postmenopausal hormone therapy (HT) and oral contraceptives (OC) (potentially modifiable); and, parity, ages at first birth, menarche and menopause (environmentally conditioned, but not readily modifiable). Modeled alterations in BMI (to all ≤23 kg/m2) and HT use (to all non-HT users) profiles resulted in a 30% reduction in predicted EC incidence rates; individually, longer duration of OC use (to all ≥10 years) resulted in a 42.5% reduction. Modeled changes in not readily modifiable exposures (i.e., those not contributing to prevention potential) resulted in ≤24.6% reduction in predicted EC incidence. Women in the lowest decile of a risk score based on the evaluated exposures had risk similar to a low risk countries; however, this was driven by relatively long use of OCs (median = 23 years). Our findings support avoidance of overweight BMI and of HT use as prevention strategies for EC in a European population; OC use must be considered in the context of benefits and risks. 相似文献
9.
10.
Petry Vanessa Bonadio Renata Colombo Cagnacci Allyne Queiroz Carneiro Senna Luiz Antonio Leite Campos Roberta do Nascimento Galvão Cotti Guilherme Cutait Hoff Paulo M. Fragoso Maria Candida Barisson Villares Estevez-Diz Maria del Pilar 《Familial cancer》2020,19(1):47-53
Familial Cancer - The risk of radiotherapy-induced malignancies (RIMs) is a concern when treating Li–Fraumeni syndrome (LFS) or Li–Fraumeni Like (LFL) patients. However, the type of... 相似文献